A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees

Vaccine

Volumn 19, Issue 32, 2001, Pages 4595-4602

  Schneider, Joerg ^a,g   Langermans, Jan A M ^b   Gilbert, Sarah C ^c   Blanchard, Tom J ^d   Twigg, Stephen ^a   Naitza, Silvia ^e   Hannan, Carolyn M ^a   Aidoo, Michael ^a   Crisanti, Andrea ^e   Robson, Kathryn J ^f   Smith, Geoffrey L ^d   Hill, Adrian V S ^a   Thomas, Alan W ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g Oxxon Pharmaccines   (United Kingdom)

Author keywords

Malaria; Prime boost; Vaccine

Indexed keywords

EPITOPE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; LIVER STAGE SPECIFIC ANTIGEN 1; MALARIA VACCINE; PARASITE ANTIGEN; PEPTIDE DERIVATIVE; PLASMID DNA; RECOMBINANT VACCINE; THROMBOSPONDIN RELATED ADHESION PROTEIN; UNCLASSIFIED DRUG; VACCINIA VACCINE;

ACTIVE IMMUNIZATION; ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANKARA VIRUS; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; ARTICLE; CELL INFILTRATION; CELL SPECIFICITY; CELL TYPE; CELLULAR IMMUNITY; CHIMPANZEE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; IMMUNOGENICITY; INFECTION PREVENTION; LIVER CELL; MALARIA FALCIPARUM; MALE; NONHUMAN; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINIA VIRUS;

ANIMALS; ANTIBODIES, PROTOZOAN; ANTIGENS, PROTOZOAN; CERCOPITHECUS AETHIOPS; CHICK EMBRYO; COS CELLS; DNA, PROTOZOAN; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPES; FIBROBLASTS; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION SCHEDULE; IMMUNIZATION, SECONDARY; LEUKOCYTES, MONONUCLEAR; MALARIA VACCINES; MALE; PAN TROGLODYTES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VACCINES, DNA; VACCINIA VIRUS;

EID: 17944369697     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00260-2     Document Type: Article

References (50)

1. Malaria vaccines
2. Biology of malarial liver stages: Implications for vaccine design
3. Field trials of an asexual blood stage malaria vaccine: Studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a phase IIb efficacy study
4. Transmission-blocking immunity against malaria and other vector-borne diseases
5. Rationale for the development of an engineered sporozoite malaria vaccine
6. MHC class I-dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei
7. Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria
8. CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria
9. Molecular analysis of the association of HLA-B53 and resistance to severe malaria
10. Identification of conserved antigenic components for a cytotoxic T lymphocyte-inducing vaccine against malaria
11. Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles
12. Circumventing genetic restriction of protection against malaria with multigene DNA immunization: CD8+ cell-, interferon gamma-, and nitric oxide-dependent immunity
13. An antimicrobial activity of cytolytic T cells mediated by granulysin
14. Precursor frequency analysis of cytotoxic T lymphocytes to pre- erythrocytic antigens of Plasmodium falciparum in West Africa
15. Comparison of numerous delivery systems for the induction of cytotoxic T lymphocytes by immunization
16. Induction of humoral and cellular immune responses to the human immunodeficiency type 1 virus in nonhuman primates by in vivo DNA inoculation
17. Applications of pox virus vectors to vaccination: An update
18. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: Implications for use as a human vaccine
19. The smallpox vaccination strain MVA: Marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism
20. The complete genomic sequence of the modified vaccinia Ankara strain: Comparison with other orthopoxviruses
21. Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara
22. Chimpanzees and supporting models in the study of malaria pre-erythrocytic stages
23. A highly conserved amino-acid sequence in thrombospondin, properdin and in proteins from sporozoites and blood stages of a human malaria parasite
24. Structure of Plasmodium falciparum liver stage antigen-1
25. DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: Immunogenicity in mice
26. Chloride secretion in the trachea of null cystic fibrosis mice: The effects of transfection with pTrial10-CFTR2
27. Nonreplicating vaccinia vector efficiently expresses recombinant genes
28. Structure and expression of a post-transcriptionally regulated malaria gene encoding a surface protein from the sexual stages of Plasmodium berghei
29. Rapid effector function in CD8+ memory T cells
30. Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs
31. Challenge of chimpanzees immunized with a recombinant canarypox-HIV-1 virus
32. Immunogenicity and efficacy testing in chimpanzees of an oral hepatitis B vaccine based on live recombinant adenovirus
33. Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization
34. Live recombinant vaccinia virus protects chimpanzees against hepatitis B
35. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination
36. DNA vaccine for hepatitis B: Evidence for immunogenicity in chimpanzees and comparison with other vaccines
37. In vivo protective anti-HIV immune responses in non-human primates through DNA immunization
38. SIV DNA vaccine trial in macaques: Post-challenge necropsy in vaccine and control groups
39. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients
40. First human trial of a DNA-based vaccine for treatment of human immunodeficiency virus type 1 infection: Safety and host response
41. Enhancing efficacy of recombinant anticancer vaccines with prime/boost regimens that use two different vectors
42. DNA vaccination against virus infection and enhancement of antiviral immunity following consecutive immunization with DNA and viral vectors
43. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine
44. Quantification of antigen specific CD8+ T cells using an ELISPOT assay
45. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules
46. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages
47. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines
48. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine
49. Chimpanzee dendritic cells with potent immunostimulatory function can be propagated from peripheral blood
50. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liver-stage antigen 3